Molecules (MDPI) Impact Factor

Data sourced from our analysis of 20,449 journals in the Clarivate JCR 2024 database.

In our pre-submission review work with manuscripts targeting Molecules, three failure patterns generate the most consistent desk rejections despite the journal's relatively high acceptance rate (~40-50%).

Scope mismatch in a deceptively broad journal. Molecules covers organic chemistry, inorganic chemistry, biochemistry, analytical chemistry, medicinal chemistry, and related fields, but "related fields" has limits. Physics papers that happen to involve molecular systems, materials science papers without molecular-level characterization, or biology papers where chemistry is incidental face desk rejection for scope mismatch. MDPI uses an academic editor pre-check specifically to assess scope fit before peer review, and this check is not a formality. The most common scope rejection is papers that are fundamentally materials science, pharmaceutical development, or food science but which include molecular characterization in the methods section. The paper's primary contribution needs to be chemistry, not a field that uses chemical analysis as a supporting tool.

Methodological shortcuts in a soundness-based review model. MDPI and Molecules use a soundness-based review model, meaning papers are evaluated primarily on methodological rigor rather than perceived novelty. This matters for understanding what gets rejected: Molecules will accept an incremental finding if the methodology is complete and the controls are sound; it will reject a potentially interesting finding if the methodology has gaps. Common rejection triggers are single-experiment conclusions without replication, absent or inadequate negative controls, missing statistical analysis, incomplete characterization of novel compounds (no NMR, MS, or purity data where expected), and analytical methods that are not validated for the reported application. The high acceptance rate reflects the lack of a novelty bar, not the absence of a quality bar.

Preliminary data presented as conclusions. Molecules rejects papers where the data support "further work is needed" conclusions rather than positive, confirmable findings. Pilot studies, feasibility demonstrations, or exploratory work that establishes a hypothesis without testing it are returned with "Reject and Encourage Resubmission" decisions. These are not permanent rejections, the journal explicitly invites resubmission after the work is more fully developed, but they mean the current manuscript is not ready. If the paper's abstract and conclusion describe what the next experiments should show rather than what the current experiments demonstrate, it needs more data before submission. A Molecules methodology and completeness check can identify whether the methodology, scope fit, and completeness meet Molecules' specific bar.

Molecules peaked in 2021 at ~4.9 during the broader MDPI citation surge, then declined. The current 4.2 likely represents the journal's post-normalization baseline. This decline pattern is typical across MDPI journals.

Submit if:

• the paper is solid molecular science (organic, natural products, medicinal chemistry)
• fast open-access publication is a priority
• the MDPI model is acceptable in your field
• more selective chemistry journals (JACS, Angewandte) aren't realistic targets

Think twice if:

• ACS Omega or RSC Advances provides similar visibility with a different publisher brand
• a specialty organic chemistry journal would reach the right audience better
• the MDPI model raises concerns in your institution

A Molecules vs higher-tier journal fit check can assess whether a more selective journal is realistic.

For Molecules, the page should help the author answer a practical tradeoff question rather than repeat the quartile. The real decision is whether the manuscript is better served by fast open-access publication in a very broad MDPI journal or by a more selective chemistry venue with a clearer community signal. That is the choice most authors are actually making when Molecules appears on the shortlist.

The metric matters because 4.2 is strong enough that the journal cannot be dismissed as invisible. But the journal's enormous scope and publisher model mean the number should be read alongside editorial selectivity, article volume, APC expectations, and how the field reads MDPI-brand chemistry papers. A decent JIF does not automatically make the journal the best home for every solid chemistry manuscript.

Another way to frame the decision is audience intent. If the paper needs immediate open-access availability, broad indexing, and a realistic path to publication, Molecules can be pragmatic. If the paper needs a journal name that itself carries stronger prestige in organic chemistry, medicinal chemistry, or natural products, the page should tell the reader that more selective options may be worth the extra risk.

The journal's citation profile has stayed good enough to keep Molecules clearly visible in multidisciplinary chemistry, but the trend is most useful as a signal of stable platform value rather than elite editorial standing. That distinction matters. Authors comparing Molecules with ACS Omega, RSC Advances, or stronger specialty journals should interpret the metric as proof of discoverability, not proof of top-tier field endorsement.

Molecules tends to make the most sense when the paper sits in a crowded middle band: publishable chemistry, sound methods, decent novelty, but not the kind of selective field-defining result that benefits from spending months testing a harder journal ladder. That can be especially true for medicinal chemistry support studies, natural-products characterization, synthetic workflows with limited conceptual reach, or cross-cutting molecular work that does not belong cleanly to one subfield title.

In those cases, the journal's breadth can actually be an advantage. A broad molecular-science venue can expose the paper to readers outside one micro-community, and the open-access model lowers access friction. But that benefit only matters if the authors are intentionally choosing speed and breadth. If they are choosing the journal because it looks easier while still wanting the signal of a higher-prestige chemistry title, the page should make clear that those are different outcomes.

The impact factor does not tell you how the paper will be read by hiring committees that distinguish sharply between MDPI and society publishers. It does not tell you whether reviewers in your exact chemistry subfield will regard the journal as a serious first-choice venue. And it does not erase the fact that, in many chemistry areas, journal identity still carries strong social meaning beyond citation averages.

That is why the right use of this page is not to ask whether 4.2 is "good enough" in the abstract. It is to ask whether the combination of moderate citation performance, fast handling, open access, and MDPI branding matches the paper's actual needs.

For authors making an honest shortlist, that extra clarity matters more than the raw quartile label because it separates a convenient outlet from a strategically strong fit.

• It helps when the manuscript needs broad chemistry visibility and fast open-access handling.
• It helps when the realistic comparison set is other broad-access chemistry journals rather than flagship titles.
• It misleads when the paper would benefit much more from a specialty journal with a clearer community identity.
• It misleads when authors treat a respectable JIF as proof that the MDPI tradeoff no longer matters.

• Molecules submission guide
• Molecules submission process
• How to avoid desk rejection at Molecules
• Is Molecules a good journal?

The impact factor for Molecules (MDPI) measures average citations per paper over 2 years. It does not measure the quality of any individual paper, the prestige within a specific subfield, or whether the journal is the right fit for your work. A high IF does not guarantee your paper will be cited, and a lower IF does not mean the journal lacks influence in its specialty.

Impact factors also do not account for field-specific citation patterns. Journals in clinical medicine accumulate citations faster than journals in mathematics or ecology. Comparing IFs across fields is misleading.

Before submitting, a Molecules submission readiness check can assess whether your manuscript fits the journal's actual editorial scope and completeness bar.